2HG	D-2-hydroxygluterate
5hmC	5-hydroxy-methylcitosine
AEs	adverse events
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AST	aspartate aminotransferase
BRSD	best response of stable disease
CTCF	CCCTC binding factor
CNS	central nervous system
CpG	5′-C-phosphate-G-3′
DLTs	dose-limiting toxicities
FDA	U.S. Food and Drug Administration
GFAP	glial fibrillary acidic protein
HRQoL	health-related quality of life
IDH	isocitrate dehydrogenase
KDMs	histone lysine demethylases
LGG	low-grade glioma
mTD	median treatment duration
NADP	nicotinamide adenine dinucleotide phosphate
NK	natural killer
ORR	objective response rate
OS	overall survival
PARP	poly ADP ribose polymerase
PCV	a combination of procarbazine, lomustine, and vincristine
PDGFRA	platelet-derived growth factor receptor A
PD-L1	programmed death ligand 1
PFS	progression-free survival
QD	once daily
RANO	Response Assessment in Neuro-Oncology
ROS	reactive oxygen species
TET	ten-eleven translocation
TGR	tumor growth rate
TILs	tumor-infiltrating lymphocytes
TME	tumor microenvironment
TRAE	treatment-related adverse events
WHO CNS	World Health Organization Classification of Tumors of the Central Nervous System
αKG	α-ketoglutarate